Kymera Investor Presentation Deck
Single Dose of KT-253 Leads to Sustained Tumor Regression and is
Superior to MDM2/p53 Small Molecule Inhibitors
RS4;11
MV4;11
Tumor Volume (mm³)
Mean ± SEM
Probability of Survival
2500
2000
1500
1000
500
0
100
75-
50
0
25
0 7
7
14
Days Post Treatment
21
T
14 21 28 35 42 49 56
Days Post Treatment
Vehicle
→ DS-3032 30 mg/kg PO, 3 on/11 off
DS-3032 100 mg/kg PO, 3 on/11 off
KT-253 0.3 mg/kg IV, QWx3
KT-253 1 mg/kg IV, SD
→ KT-253 3 mg/kg IV, SD
28
-
Vehicle Control
DS-3032 30 mg/kg PO, 3 on/11 off
DS-3032 100 mg/kg PO, 3 on/11 off
KT-253 0.3 mg/kg IV, QWx3
KT-253 1 mg/kg IV, SD
KT-253 3 mg/kg IV, SD
Tumor Volume (mm³)
Mean ± SEM
Probability of Survival
2500
2000-
1500
1000
500
0
100
75
50
25
0
0
0
7
7
14
Days Post Treatment
ILL
21
28
14 21 28 35 42 49 56 63 70
Days Post Treatment
Vehicle Control
→DS-3032 30 mg/kg PO, 3 on/11 off
DS-3032 100 mg/kg PO, 3 on/11 off
KT-253 1 mg/kg IV QWx3
KT-253 3 mg/kg IV, SD
Vehicle Control
DS-3032 30 mg/kg PO, 3 on/11 off
DS-3032 100 mg/kg PO, 3 on/11 off
KT-253 1 mg/kg IV, QWx3
KT-253 3 mg/kg IV, SD
RS4;11 ALL model, the median survival after a single dose of KT-253 at 3 mg/kg was 50 days vs 12 days for the
clinically equivalent dosing regimen of DS-3032.
MV4;11 AML model, a single dose of KT-253 at 3 mg/kg led to complete responses in 5 of 6 animals, and 4 of 6 remain
tumor-free on study 80 days post dosing.
KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC.
PAGE 54View entire presentation